CORE Biomedicine Licenses Precision Oncology Programs from Eisai
CORE Biomedicine has signed an exclusive licensing agreement with Eisai Co., Ltd. to develop and commercialize multiple preclinical oncology programs globally. These programs, originally discovered by Eisai and its affiliates, target key molecular drivers of various cancers and span distinct biological pathways. The deal provides CORE with a strong foundation for building a next-generation precision medicine company focused on translating cancer biology into transformative therapies. CORE Biomedicine was founded to advance innovative oncology programs grounded in deep scientific understanding and precision medicine. Dr. Douglas McMillin, Co-Founder of the company, emphasized that these licensed assets have significant potential to address unmet medical needs across multiple cancers. The agreement supports CORE's strategy for efficient clinical development. Eisai is a global pharmaceutical firm with a focus on neurology and oncology, aiming to deliver innovative products through its extensive R&D network.
Topics: Biotechnology Drug Development Oncology Pharmaceuticals